Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia

Simple item page
cg.authorship.typesCGIAR and developing country institute
cg.contributor.affiliationKenya Agricultural and Livestock Research Organization
cg.contributor.affiliationVaccine Infectious Disease Organization
cg.contributor.affiliationInternational Livestock Research Institute
cg.contributor.affiliationUniversity of Nairobi
cg.contributor.affiliationUniversity of Bern
cg.creator.identifierJan Naessens: 0000-0002-7075-9915
cg.creator.identifierAnne Liljander: 0000-0002-7543-5493
cg.creator.identifierJoerg Jores: 0000-0003-3790-5746
cg.howPublishedFormally Published
cg.identifier.doihttps://doi.org/10.1016/j.vetimm.2016.02.010
cg.isijournalISI Journal
cg.issn0165-2427
cg.journalVeterinary Immunology and Immunopathology
cg.reviewStatusPeer Review
cg.subject.ilriANIMAL DISEASES
cg.subject.ilriCBPP
cg.subject.ilriDISEASE CONTROL
cg.subject.ilriLIVESTOCK
cg.subject.ilriVACCINES
cg.volume171
dc.contributor.authorNkando, I.
dc.contributor.authorPérez Casal, J.
dc.contributor.authorMwirigi, M.
dc.contributor.authorPrysliak, T.
dc.contributor.authorTownsend, H.
dc.contributor.authorBerberov, E.
dc.contributor.authorKuria, J.
dc.contributor.authorMugambi, J.
dc.contributor.authorSoi, R.
dc.contributor.authorLiljander, Anne M.
dc.contributor.authorJores, Joerg
dc.contributor.authorGerdts, V.
dc.contributor.authorPotter, A.
dc.contributor.authorNaessens, Jan
dc.contributor.authorWesonga, H.O.
dc.date.accessioned2016-03-28T20:40:13Zen
dc.date.available2016-03-28T20:40:13Zen
dc.identifier.urihttps://hdl.handle.net/10568/72741
dc.titleRecombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumoniaen
dcterms.abstractMycoplasma mycoides subsp. mycoides (Mmm) is the causative agent of contagious bovine pleuropneumonia (CBPP), a devastating respiratory disease mainly affecting cattle in sub-Saharan Africa. The current vaccines are based on live-attenuated Mmmstrains and present problems with temperature stability, duration of immunity and adverse reactions, thus new vaccines are needed to overcome these issues. We used a reverse vaccinology approach to identify 66 Mmm potential vaccine candidates. The selection and grouping of the antigens was based on the presence of specific antibodies in sera from CBPP-positive animals. The antigens were used to immunize male Boran cattle (Bos indicus) followed by a challenge with the Mmm strain Afadé. Two of the groups immunized with five proteins each showed protection after the Mmm challenge (Groups A and C; P < 0.05) and in one group (Group C) Mmm could not be cultured from lung specimens. A third group (Group N) showed a reduced number of animals with lesions and the cultures for Mmm were also negative. While immunization with some of the antigens conferred protection, others may have increased immune-related pathology. This is the first report that Mmm recombinant proteins have been successfully used to formulate a prototype vaccine and these results pave the way for the development of a novel commercial vaccine.en
dcterms.accessRightsLimited Access
dcterms.audienceScientists
dcterms.bibliographicCitationNkando, I., Perez-Casal, J., Mwirigi, M., Prysliak, T., Townsend, H., Berberov, E., Kuria, J., Mugambi, J., Soi, R., Liljander, A., Jores, J., Gerdts, V., Potter, A., Naessens, J. and Wesonga, H. 2016. Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia. Veterinary Immunology and Immunopathology 171:103–114.en
dcterms.extentp. 103-114
dcterms.issued2016-03
dcterms.languageen
dcterms.licenseCopyrighted; all rights reserved
dcterms.publisherElsevier
dcterms.subjectanimal diseasesen
dcterms.subjectdisease controlen
dcterms.typeJournal Article

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ILRI articles in journals
ILRI vaccine biosciences program outputs